-
公开(公告)号：US12110337B2
公开(公告)日：2024-10-08
申请号：US17045143
申请日：2019-04-03
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Li-Sheng Lu , Mark J. Selby , Alan J. Korman , Shrikant Deshpande , Mohan Srinivasan , Jun Zhang , Haichun Huang , Guodong Chen , Richard Y. Huang , Ekaterina Deyanova
IPC: C07K16/28 , A61K39/395 , A61P35/00 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/39541 , A61P35/00 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/74 , C07K2317/75 , C07K2317/92
Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.
-
公开(公告)号：US11623965B2
公开(公告)日：2023-04-11
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, Jr. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
3.发明授权公开(公告)号：US11084881B2
公开(公告)日：2021-08-10
申请号：US16578987
申请日：2019-09-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C12N15/13 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00 , A61K47/68
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US10556948B2
公开(公告)日：2020-02-11
申请号：US15364612
申请日：2016-11-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
5.发明授权公开(公告)号：US10465010B2
公开(公告)日：2019-11-05
申请号：US15646558
申请日：2017-07-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C07K16/00 , C07H21/00 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00 , A61K47/68
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
Patent Agency Ranking
公开(公告)号：US10358490B2
公开(公告)日：2019-07-23
申请号：US15694374
申请日：2017-09-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: A61K39/395 , C07K16/24 , C07K16/46 , A61K39/00
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
7.发明授权公开(公告)号：US10266591B2
公开(公告)日：2019-04-23
申请号：US15296290
申请日：2016-10-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Mohan Srinivasan
Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
8.发明申请公开(公告)号：US20180371087A1
公开(公告)日：2018-12-27
申请号：US16125028
申请日：2018-09-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Mohan Srinivasan
CPC classification number: C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2818 , C07K16/2827 , C07K16/3061 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US10100129B2
公开(公告)日：2018-10-16
申请号：US15520638
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/00 , C07K16/40 , C07K16/28 , A61K47/68 , C07K16/30 , A61K39/395 , A61K45/06 , G01N33/574
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
公开(公告)号：US20160176963A1
公开(公告)日：2016-06-23
申请号：US14977789
申请日：2015-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： Mark F. Maurer , Tseng-hui Timothy Chen , Brigitte Devaux , Mohan Srinivasan , Susan H. Julien , Paul O. Sheppard , Daniel F. Ardourel , Indrani Chakraborty
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y02A50/466
Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
Abstract translation: 本发明提供了结合人TIGIT（具有Ig和ITIM结构域的T细胞免疫受体）的抗体或其抗原结合片段，以及这些抗体或片段在治疗应用中的用途，例如用于治疗癌症或慢性 病毒感染。 这种治疗方法包括与其它免疫调节受体相互作用的抑制剂如PD-1 / PD-L1相互作用的联合治疗。 本发明还提供了编码抗体的重链和/或轻链可变区的多核苷酸，包含编码抗体的重链和/或轻链可变区的多核苷酸的表达载体，包含载体的细胞，以及制备抗体或 片段通过从细胞表达。
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.044 seconds)
